COMMUNIQUÉS West-GlobeNewswire

GENFIT : RESULTATS DU PREMIER SEMESTRE 2017 : TRESORERIE DE CLOTURE DE 126 M€ ET AVANCEES MAJEURES DANS LE DEVELOPPEMENT DU PORTEFEUILLE DE PRODUITS ET PROGRAMMES DE LA SOCIETE
25/09/2017
RESULTATS DU PREMIER SEMESTRE 2017 : TRESORERIE DE CLOTURE DE 126 M€ ET AVANCEES MAJEURES DANS LE DEVELOPPEMENT DU PORTEFEUILLE DE PRODUITS ET PROGRAMMES DE LA SOCIETE - Résultats semestriels traduisant la progression [...]
GENFIT: 2017 HALF-YEAR RESULTS: CASH POSITION AT END OF PERIOD AT €126M AND SIGNIFICANT ADVANCES IN THE COMPANY'S PIPELINE
25/09/2017
2017 HALF-YEAR Results: Cash position at end of period at €126M and significant advances in the Company's pipeline - Half year results reflect the progress of elafibranor Phase 3 RESOLVE-IT study in NASH - Launch of the [...]
Sanofi : Disclosure of trading in own shares
25/09/2017
Reporting EN This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, [...]
Sanofi : Déclaration des transactions sur actions propres
25/09/2017
Reporting FR This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, [...]
Ossur Hf : Transactions in relation to share buyback program
25/09/2017
Announcement from Össur hf. No. 69/2017 Reykjavík, 25 September 2017 On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017. The purpose of the share buyback program is to [...]
Ossur Hf : Össur announces efficiency initiatives
25/09/2017
Announcement no. 68/2017 Reykjavík, 25 September 2017 Össur announces efficiency initiatives At the Capital Markets Day in Copenhagen on 27 September 2017, Össur's management will elaborate on growth, innovation, and [...]
Enzymatica AB: Notice of extraordinary general meeting regarding among other things personnel option program in Enzymatica AB (publ)
25/09/2017
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Press release Lund on September 25, 2017 Notice of [...]
ProLynx announces SBIR grant award to develop novel technology for dual receptor agonists
25/09/2017
SAN FRANCISCO, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Today, ProLynx announced it was awarded a Small Business Innovation Research (SBIR) grant from the NIH to expand its technology platform to control delivery of two or [...]
Novo Nordisk A/S - Share repurchase programme
25/09/2017
Bagsværd, Denmark, 25 September 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]
Summit Joins cTAP in Effort to Enhance Development of Utrophin Modulators and Other Treatments for DMD
25/09/2017
Summit Therapeutics plc ('Summit', or 'the Company') SUMMIT JOINS cTAP IN COLLABORATIVE EFFORT TO ENHANCE THE DEVELOPMENT OF UTROPHIN MODULATORS AND OTHER TREATMENTS FOR DUCHENNE MUSCULAR DYSTROPHY Oxford, UK, 25 [...]
argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis
25/09/2017
Non-regulated information September 25, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody- [...]
HomeVi announces the launch of syndication of EUR 1,020 million Senior Secured Term Loan B for debt refinancing
25/09/2017
Suresnes, September 25, 2017 - 8:30 am CET HomeVi S.A.S. ("HomeVi") today announced that it will shortly begin syndicating a Senior Secured Term Loan B of EUR 1,020 million and a Senior Secured Revolving Credit Facility [...]
Ambu A/S: Patient safety made simpler with innovative visualisation devices
25/09/2017
Integration of VivaSight further strengthens Ambu's aScope solution. In 2016, Ambu acquired Israeli company ETView and thereby the VivaSight products - single-use double-lumen and single-lumen tubes with integrated high [...]
Ambu A/S: Ambu launches 4th generation of single-use bronchoscopes
25/09/2017
Innovation: 'Ambu ® aScope TM 4 Broncho' unveiled today in Vienna at European intensive care congress. Improved image quality means that Ambu expects new scope to be relevant for 50% more hospital procedures. Over the [...]
Targovax granted US Patent for mutant-RAS neoantigen platform lead products
25/09/2017
Extends IP protection of TG01 and TG02 until 06.05.2034 Oslo, 25 September 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target [...]
IBA SA : IBA et Elekta signent un protocole d'entente portant sur le développement conjoint de software et de ventes pour soutenir le développement de la protonthérapie
23/09/2017
IBA et Elekta signent un protocole d'entente portant sur le développement conjoint de software et de ventes pour soutenir le développement de la protonthérapie SAN DIEGO, Etats-Unis, 23 septembre 2017 - IBA (Ion Beam [...]
IBA SA : IBA and Elekta enter an MOU regarding a comprehensive partnership including joint software development and sales to advance proton therapy treatments
23/09/2017
IBA and Elekta enter an MOU regarding a comprehensive partnership including joint software development and sales to advance proton therapy treatments SAN DIEGO, September 23, 2017 - IBA (Ion Beam Applications) and [...]
Abiomed obtient l'autorisation APMM de la FDA pour l'Impella RP® pour l'insuffisance cardiaque droite
22/09/2017
DANVERS, Massachusetts, le 22 septembre 2017 (GLOBE NEWSWIRE) - Abiomed, Inc. (NASDAQ : ABMD), fournisseur majeur de technologies innovantes d'assistance et de récupération cardiaque, a annoncé aujourd'hui qu'elle a [...]
Le portefeuille de propriété intellectuelle de Merus s'enrichit de deux nouveaux brevets grâce à sa technologie Biclonics®
22/09/2017
UTRECHT, Pays-Bas, le 20 septembre 2017 (GLOBE NEWSWIRE). -- Merus (NASDAQ : MRUS), société spécialisée en immuno-oncologie au stade clinique qui développe des traitements visant à guérir des maladies graves, a annoncé [...]

Pages